about
Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewThe Place of FDG PET/CT in Renal Cell Carcinoma: Value and LimitationsLinkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?Current status of partial nephrectomy for renal mass.Simplified zero ischemia in robot assisted partial nephrectomy: initial yonsei experience.Laparoscopic partial nephrectomy: integration of an advanced laparoscopic technique.Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.Peritumoral Artery Scoring System: a Novel Scoring System to Predict Renal Function Outcome after Laparoscopic Partial NephrectomyRoles for the type III TGF-beta receptor in human cancerHaemostatics in surgery and our experience in the enucleoresection of renal cell carcinoma.Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications.Comparison of robotic and open partial nephrectomy: Single-surgeon matched cohort study.Renal cell carcinoma metastasis to the ciliary body responds to proton beam radiotherapy: a case report.Comparison of Partial and Radical Nephrectomy for pT1b Renal Cell Carcinoma.Targeted therapies in the management of renal cell carcinoma: role of bevacizumabSingle nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinomaEvaluation of national trends in the utilization of partial nephrectomy in relation to the publication of the American Urologic Association guidelines for the management of clinical T1 renal masses.Robotic-assisted partial nephrectomy: Has it come of age?Renal endometriosis tends to be misdiagnosed as renal tumor: a rare case report.Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.Transglutaminase 2 expression and its prognostic significance in clear cell renal cell carcinoma.The renal tumor morphological characteristics that affect surgical planning for laparoscopic or open partial nephrectomy.Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index.Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinomaInhibition of γ-secretase by retinoic acid chalcone (RAC) induces G2/M arrest and triggers apoptosis in renal cell carcinomaTumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.Pseudocapsule of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: a clue for tumor enucleation?Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms.Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.Comparison of guideline recommendations with daily practice in patients with renal cell carcinoma.Mini-flank supra-12th rib incision for open partial nephrectomy for renal tumor with RENAL nephrometry score ≥10: an innovation of traditional open surgery.Comparison of the Width of Peritumoral Surgical Margin in Open and Robotic Partial Nephrectomy: A Propensity Score Matched Analysis.Novel agents in renal carcinoma: a reality check.Tc-99m Hydroxymethylene Diphosphonate (HMDP) Renal Uptake as a Surrogate Marker of Postoperative Impairment of the Glomerular Filtration Rate in Renal Tumor Patients Following Nephron-Sparing Surgery.Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.Denosumab: a new option in the treatment of bone metastases from urological cancersCyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma.
P2860
Q26774515-B4B5D84E-EB3B-4A4F-9BC7-B6E6EDBB74A2Q28070239-7641FC43-6B95-4A7E-AAA6-E1DEF7D6A072Q30318519-84E8C443-0D11-4946-9ABE-818CD388FA02Q30475125-4D17CDDE-A004-47EC-A944-AC52117164FEQ30536422-F3AEC4DD-286B-4B2C-94E4-0F29386864E4Q33340105-E95CFB94-FEC5-4E6E-A280-DA0618476DD2Q33514834-2EEF40B0-BE8F-49B8-8D44-F3D92DD8F593Q33757520-E710E1C0-4448-4B1C-AAAE-73A9DCAA90CEQ33767501-92BB683E-0BC6-4BED-AB3B-A5C4706AC4CDQ33872593-79811A10-6E8A-4569-9AEF-D3C6A4EBED76Q33875718-C17CFFE9-CB00-45EA-B51D-A82D39384AFFQ33944741-8A9DB2DA-FAE7-4C97-97F9-5062D2AE2121Q33962384-93A67135-AA1B-4EE5-A1AE-CBA1A854E92AQ33980603-CF43EB2B-F5B7-4DC5-AA2B-329CB39B7DD6Q34139194-A04BDD1A-697E-4FA4-A0DE-98D878AB967AQ34611205-5939261D-60B2-4EE7-B9F6-8329EC209E65Q34618828-237137F0-288E-473B-9AC6-7F3FC44AFB57Q34901035-40457B36-20CB-4D85-BB39-76CE3306725AQ35015698-D7D7E51F-5FB8-402F-8679-6BEEE4A1F85AQ35110737-00389FC7-436F-451F-A32E-E0532CE3B635Q35118187-8FF21992-6C68-4B9B-88C6-A776E6833C3FQ35154954-B75A1FA9-B3D3-4450-8C83-BC390848E800Q35170748-32266BC6-BA13-4989-8E39-FC5347089F8CQ35182003-8C134247-342F-4276-8BE0-BBFA46D3E507Q35182385-5B7F3E44-8278-4FA0-A780-6E4DF104E5FAQ35592187-65C8E5C6-7D3B-4174-B22D-89BD22396299Q35632027-296DA040-CBC6-4F6F-823E-366C7E18D9B4Q35713525-B8150269-6EFC-4780-832D-1B548EF49D5BQ35835132-C0C0140A-10CE-46BE-AA17-081DCEC9EE66Q35854182-689F790A-1FC4-4464-8046-F761C8B9ABBCQ35854397-0F594196-CD08-47D1-94E3-AA489AD3E373Q35958973-E75CA03E-B7CD-4A87-857F-5FEEE9548D80Q35959177-129DAA31-420A-4E47-83FB-B2034F92D37FQ36009162-4D31B6E0-2482-4ABC-85C5-A9A868EB76F2Q36059885-FEB1A815-0BE7-40CF-AAEE-F7FB32A28056Q36061173-234EA5C0-CBC1-4B99-98B5-E7467060BC5DQ36064580-4A7A8F94-E791-4E0E-9BD3-FEFDAFB24797Q36252946-F95BED08-B39E-48A0-BD4A-62F0A779DAD2Q36277837-3FB35D15-AA39-4C4A-9FB5-A713739217B2Q36343530-0AA2303B-1B7C-4983-83B6-DC3F9E12FA91
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Renal cell carcinoma guideline.
@ast
Renal cell carcinoma guideline.
@en
Renal cell carcinoma guideline.
@nl
type
label
Renal cell carcinoma guideline.
@ast
Renal cell carcinoma guideline.
@en
Renal cell carcinoma guideline.
@nl
prefLabel
Renal cell carcinoma guideline.
@ast
Renal cell carcinoma guideline.
@en
Renal cell carcinoma guideline.
@nl
P2093
P1433
P1476
Renal cell carcinoma guideline.
@en
P2093
Axel S Merseburger
Damian C Hanbury
European Association of Urology Guideline Group for renal cell carcinoma
Ioanel C Sinescu
Marcus A Kuczyk
Peter F A Mulders
P304
P356
10.1016/J.EURURO.2007.03.035
P407
P577
2007-03-28T00:00:00Z